kabutan

Heartseed Inc.(219A) Summary

219A
TSE Growth
Heartseed Inc.
1,787
JPY
+269
(+17.72%)
Dec 5, 11:30 am JST
11.52
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
1,786.1
Dec 5, 11:29 am JST
Summary Chart Historical News Financial Result
PER
444.5
PBR
5.67
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:15 am
1,758 JPY 11.33 USD
Previous Close Dec 4
1,518 JPY 9.77 USD
High Dec 5, 9:40 am
1,818 JPY 11.71 USD
Low Dec 5, 9:17 am
1,632 JPY 10.51 USD
Volume
2,639,900
Trading Value
4.65B JPY 0.03B USD
VWAP
1759.96 JPY 11.35 USD
Minimum Trading Value
178,700 JPY 1,152 USD
Market Cap
0.04T JPY 0.26B USD
Number of Trades
10,254
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
4,238
1-Year High Oct 2, 2025
50,688
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 758,800 2,063,100 2.72
Nov 21, 2025 765,000 2,090,700 2.73
Nov 14, 2025 768,600 2,141,700 2.79
Nov 7, 2025 780,800 2,302,500 2.95
Oct 31, 2025 784,400 2,173,400 2.77
Company Profile
Heartseed Inc. engages in the research and development of regenerative medicine products using iPS cells for cardiac regeneration.
Sector
Pharmaceuticals
Heartseed Inc. is a regenerative medicine venture originating from Keio University. The company is advancing the development of "cardiac regenerative medicine," a treatment method that involves transplanting micro-tissues (cardiac spheroids) derived from iPS cell-based cardiomyocytes into the heart, aiming to establish safety and efficacy. Heartseed possesses proprietary technologies, including techniques for producing high-purity cardiomyocytes and transplantation devices. With a vision for global expansion of cardiac regenerative medicine using allogeneic iPS cell-derived cardiac spheroids, the company entered into an exclusive worldwide technology partnership and licensing agreement with Novo Nordisk, a global pharmaceutical giant headquartered in Denmark, in May 2021.